Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Jan;31(1):65–71. doi: 10.1111/j.1365-2125.1991.tb03858.x

Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects.

J G Larkin 1, P J McKee 1, G Forrest 1, G H Beastall 1, B K Park 1, J I Lowrie 1, P Lloyd 1, M J Brodie 1
PMCID: PMC1368413  PMID: 2015172

Abstract

1. Oxcarbazepine (OXC), the 10-keto analogue of carbamazepine (CBZ), has similar anticonvulsant efficacy and possibly improved patient tolerability. Unlike CBZ, it is metabolised by reduction and may not induce hepatic monooxygenase enzymes. 2. Serum concentrations of OXC and its active metabolite 10-OH-carbazepine (10-OH-CZ) were followed after a single 300 mg dose and during and after 300 mg OXC twice daily for 29 doses in eight healthy male volunteers. 3. Antipyrine metabolism, urinary 6-beta-hydroxycortisol excretion, sex hormone binding globulin (SHBG) levels and circulating androgens were measured as indices of hepatic enzyme induction before, during and after treatment with OXC. 4. Elimination half-lives (mean +/- s.e. mean) of 10-OH-CZ were unaltered by 2 weeks' therapy with OXC (before 11.3 +/- 1.1 h; after 13.9 +/- 3 h). Trough plasma concentrations of 10-OH-CZ at steady-state (31 +/- 2.2 mumol l-1) were higher than predicted (16.5 +/- 4 mumol l-1). 5. Antipyrine metabolism, urinary 6-beta-hydroxycortisol excretion, SHBG levels and circulating androgens were unaltered by treatment with OXC. 6. OXC (600 mg daily) does not induce hepatic monooxygenase enzymes and so is likely to have more predictable dose-concentration relationships and to produce fewer physiological and pharmacological interactions than CBZ.

Full text

PDF
65

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bachur N. R. Cytoplasmic aldo-keto reductases: a class of drug metabolizing enzymes. Science. 1976 Aug 13;193(4253):595–597. doi: 10.1126/science.959821. [DOI] [PubMed] [Google Scholar]
  2. Baciewicz A. M. Carbamazepine drug interactions. Ther Drug Monit. 1986;8(3):305–317. doi: 10.1097/00007691-198609000-00012. [DOI] [PubMed] [Google Scholar]
  3. Connell J. M., Rapeport W. G., Beastall G. H., Brodie M. J. Changes in circulating androgens during short term carbamazepine therapy. Br J Clin Pharmacol. 1984 Mar;17(3):347–351. doi: 10.1111/j.1365-2125.1984.tb02352.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dam M., Ekberg R., Løyning Y., Waltimo O., Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 1989 Jan-Feb;3(1):70–76. doi: 10.1016/0920-1211(89)90070-3. [DOI] [PubMed] [Google Scholar]
  5. Eichelbaum M., Ekbom K., Bertilsson L., Ringberger V. A., Rane A. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol. 1975 Jun 13;8(5):337–341. doi: 10.1007/BF00562659. [DOI] [PubMed] [Google Scholar]
  6. Gillham R. A., Williams N., Wiedmann K., Butler E., Larkin J. G., Brodie M. J. Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients. J Neurol Neurosurg Psychiatry. 1988 Jul;51(7):929–933. doi: 10.1136/jnnp.51.7.929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Herzog A. G., Seibel M. M., Schomer D. L., Vaitukaitis J. L., Geschwind N. Reproductive endocrine disorders in men with partial seizures of temporal lobe origin. Arch Neurol. 1986 Apr;43(4):347–350. doi: 10.1001/archneur.1986.00520040035015. [DOI] [PubMed] [Google Scholar]
  8. Hierons R., Saunders M. Impotence in patients with temporal-lobe lesions. Lancet. 1966 Oct 8;2(7467):761–763. doi: 10.1016/s0140-6736(66)90361-8. [DOI] [PubMed] [Google Scholar]
  9. Houtkooper M. A., Lammertsma A., Meyer J. W., Goedhart D. M., Meinardi H., van Oorschot C. A., Blom G. F., Höppener R. J., Hulsman J. A. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine? Epilepsia. 1987 Nov-Dec;28(6):693–698. doi: 10.1111/j.1528-1157.1987.tb03702.x. [DOI] [PubMed] [Google Scholar]
  10. Larkin J. G., Macphee G. J., Beastall G. H., Brodie M. J. Thyroid hormone concentrations in epileptic patients. Eur J Clin Pharmacol. 1989;36(3):213–216. doi: 10.1007/BF00558149. [DOI] [PubMed] [Google Scholar]
  11. Larkin J. G., McLellan A., Munday A., Sutherland M., Butler E., Brodie M. J. A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects. Br J Clin Pharmacol. 1989 Mar;27(3):313–322. doi: 10.1111/j.1365-2125.1989.tb05371.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Macphee G. J., Brodie M. J. Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism. Postgrad Med J. 1985 Sep;61(719):779–783. doi: 10.1136/pgmj.61.719.779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Macphee G. J., Butler E., Brodie M. J. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism. Epilepsia. 1987 May-Jun;28(3):286–294. doi: 10.1111/j.1528-1157.1987.tb04220.x. [DOI] [PubMed] [Google Scholar]
  14. Macphee G. J., Larkin J. G., Butler E., Beastall G. H., Brodie M. J. Circulating hormones and pituitary responsiveness in young epileptic men receiving long-term antiepileptic medication. Epilepsia. 1988 Jul-Aug;29(4):468–475. doi: 10.1111/j.1528-1157.1988.tb03747.x. [DOI] [PubMed] [Google Scholar]
  15. Macphee G. J., Thompson G. G., Scobie G., Agnew E., Park B. K., Murray T., McColl K. E., Brodie M. J. Effects of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol. 1984 Sep;18(3):411–419. doi: 10.1111/j.1365-2125.1984.tb02483.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mattson R. H., Cramer J. A. Epilepsy, sex hormones, and antiepileptic drugs. Epilepsia. 1985;26 (Suppl 1):S40–S51. doi: 10.1111/j.1528-1157.1985.tb05723.x. [DOI] [PubMed] [Google Scholar]
  17. Mikati M. A., Browne T. R., Collins J. F. Time course of carbamazepine autoinduction. The VA Cooperative Study No.118 Group. Neurology. 1989 Apr;39(4):592–594. doi: 10.1212/wnl.39.4.592. [DOI] [PubMed] [Google Scholar]
  18. Nielsen O. A., Johannessen A. C., Bardrum B. Oxcarbazepine-induced hyponatremia, a cross-sectional study. Epilepsy Res. 1988 Jul-Aug;2(4):269–271. doi: 10.1016/0920-1211(88)90018-6. [DOI] [PubMed] [Google Scholar]
  19. Park B. K. A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine. J Steroid Biochem. 1978 Oct;9(10):963–966. doi: 10.1016/0022-4731(78)90058-4. [DOI] [PubMed] [Google Scholar]
  20. Park B. K. Assessment of the drug metabolism capacity of the liver. Br J Clin Pharmacol. 1982 Nov;14(5):631–651. doi: 10.1111/j.1365-2125.1982.tb04950.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Patsalos P. N., Stephenson T. J., Krishna S., Elyas A. A., Lascelles P. T., Wiles C. M. Side-effects induced by carbamazepine-10,11-epoxide. Lancet. 1985 Aug 31;2(8453):496–496. doi: 10.1016/s0140-6736(85)90420-9. [DOI] [PubMed] [Google Scholar]
  22. Rapeport W. G., McInnes G. T., Thompson G. G., Forrest G., Park B. K., Brodie M. J. Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine. Br J Clin Pharmacol. 1983 Aug;16(2):133–137. doi: 10.1111/j.1365-2125.1983.tb04976.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Reinikainen K. J., Keränen T., Halonen T., Komulainen H., Riekkinen P. J. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res. 1987 Sep;1(5):284–289. doi: 10.1016/0920-1211(87)90003-9. [DOI] [PubMed] [Google Scholar]
  24. Rimmer E. M., Routledge P. A., Tsanaclis L. M., Richens A. Pharmacokinetics of antipyrine in epileptic patients. Br J Clin Pharmacol. 1986 May;21(5):511–514. doi: 10.1111/j.1365-2125.1986.tb02833.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Roots I., Holbe R., Hövermann W., Nigam S., Heinemeyer G., Hildebrandt A. G. Quantitative determination by HPLC of urinary 6beta-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs. Eur J Clin Pharmacol. 1979 Aug;16(1):63–71. doi: 10.1007/BF00644969. [DOI] [PubMed] [Google Scholar]
  26. Schütz H., Feldmann K. F., Faigle J. W., Kriemler H. P., Winkler T. The metabolism of 14C-oxcarbazepine in man. Xenobiotica. 1986 Aug;16(8):769–778. doi: 10.3109/00498258609043567. [DOI] [PubMed] [Google Scholar]
  27. Theisohn M., Heimann G. Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers. Eur J Clin Pharmacol. 1982;22(6):545–551. doi: 10.1007/BF00609629. [DOI] [PubMed] [Google Scholar]
  28. Wagner J., Schmid K. Induction of microsomal enzymes in rat liver by oxcarbazepine, 10,11-dihydro-10-hydroxy-carbamazepine and carbamazepine. Xenobiotica. 1987 Aug;17(8):951–956. doi: 10.3109/00498258709044193. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES